

Cover Story
Guest Editorial
By John H. Stewart and Robert A. Winn
Advances in the field of tumor immunotherapy have given great hope for those treating cancer. We are in an era of unprecedented achievements, as evidenced by impressive clinical responses in patients treated with adoptive cell therapy and immune checkpoint inhibitors.
By Claire Dietz and Matthew Bin Han Ong
In Brief
Clinical Roundup


Drugs & Targets


NCI Trials


NCI Trials for May
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
Trending Stories
- Gardiner Harris, acclaimed health care and pharma journalist, on his New York Times bestselling book
- Knight Cancer Institute receives record-setting $2B gift from the Knights—and self-governance within OHSU
Brian Druker returns to executive role as president of the new Knight Cancer Group - ACOG says it will no longer accept federal funding
- Duke Officials Silenced Med Student Who Reported Trouble in Anil Potti’s Lab
- The Med Student’s Memo – Research Concerns
- ANCHOR trial shows that treatment of anal high-grade squamous intraepithelial lesions prevents anal cancer in people with HIV